Skip to main content
. 2014 Aug 1;180(6):636–644. doi: 10.1093/aje/kwu162

Table 2.

Case-Crossover, Control-Crossover, and Exposure Time Trend Adjusted Estimates, Medicaid Analytic eXtracts, 2000–2006

Monitoring Dates
Case-Crossover
Control-Crossovera
Case-Time-Control
Start End EOR 95% CI EOR 95% CI EOR 95% CI
Valdecoxib (Outcome: Acute Myocardial Infarction)
November 1, 2001 June 30, 2002 MNC 38.52 32.03, 46.31 MNC
November 1, 2001 September 30, 2002 12.00 4.33, 33.28 4.55 4.37, 4.74 2.64 0.95, 7.32
November 1, 2001 December 31, 2002 4.88 2.90, 8.23 2.65 2.59, 2.72 1.84 1.09, 3.10
November 1, 2001 March 31, 2003 3.32 2.22, 4.96 1.90 1.86, 1.94 1.75 1.17, 2.62
November 1, 2001 June 30, 2003 2.77 1.98, 3.86 1.69 1.66, 1.72 1.64 1.17, 2.29
November 1, 2001 September 30, 2003 2.65 1.95, 3.59 1.56 1.54, 1.58 1.70 1.25, 2.31
November 1, 2001 December 31, 2003 2.28 1.75, 2.98 1.53 1.51, 1.55 1.49 1.14, 1.95
November 1, 2001 March 31, 2004 1.96 1.55, 2.48 1.43 1.41, 1.45 1.37 1.08, 1.74
November 1, 2001 June 30, 2004 1.72 1.38, 2.13 1.40 1.38, 1.41 1.23 0.99, 1.52
November 1, 2001 September, 30, 2004 1.66 1.36, 2.04 1.37 1.36, 1.38 1.21 0.99, 1.49
November 1, 2001 December 31, 2004 1.62 1.34, 1.97 1.36 1.35, 1.38 1.19 0.98, 1.44
November 1, 2001 March 31, 2005 1.56 1.29, 1.88 1.27 1.26, 1.28 1.22 1.01, 1.48
November 1, 2001 June 30, 2005 1.47 1.22, 1.77 1.20 1.19, 1.21 1.23 1.02, 1.48
November 1, 2001 September 30, 2005 1.41 1.18, 1.69 1.16 1.15, 1.17 1.22 1.01, 1.46
November 1, 2001 December 31, 2005 1.41 1.18, 1.69 1.16 1.15, 1.17 1.22 1.01, 1.46
Aripiprazole (Outcome: Acute Myocardial Infarction)
November 15, 2002 June 30, 2003 MNC 5.31 4.92, 5.74 MNC
November 15, 2002 September 30, 2003 2.67 0.71, 10.05 3.14 3.00, 3.29 0.85 0.23, 3.20
November 15, 2002 December 31, 2003 3.29 1.41, 7.66 2.51 2.42, 2.60 1.31 0.56, 3.05
November 15, 2002 March 31, 2004 3.00 1.47, 6.14 2.19 2.12, 2.25 1.37 0.67, 2.81
November 15, 2002 June 30, 2004 3.33 1.75, 6.35 2.05 2.00, 2.10 1.63 0.85, 3.10
November 15, 2002 September 30, 2004 2.40 1.42, 4.04 2.02 1.98, 2.07 1.19 0.70, 2.00
November 15, 2002 December 31, 2004 2.52 1.56, 4.09 1.89 1.86, 1.93 1.33 0.82, 2.16
November 15, 2002 March 31, 2005 2.13 1.38, 3.29 1.84 1.80, 1.87 1.16 0.75, 1.79
November 15, 2002 June 30, 2005 2.33 1.55, 3.51 1.79 1.76, 1.82 1.30 0.87, 1.96
November 15, 2002 September 30, 2005 2.16 1.47, 3.17 1.74 1.71, 1.77 1.24 0.85, 1.83
November 15, 2002 December 31, 2005 2.09 1.46, 3.01 1.69 1.67, 1.72 1.24 0.86, 1.78
November 15, 2002 March 31, 2006 1.81 1.29, 2.54 1.64 1.62, 1.67 1.10 0.78, 1.55
November 15, 2002 June 30, 2006 1.80 1.30, 2.50 1.60 1.57, 1.62 1.13 0.81, 1.57
November 15, 2002 September 30, 2006 1.68 1.23, 2.28 1.55 1.52, 1.57 1.08 0.80, 1.47
November 15, 2002 December 31, 2006 1.54 1.15, 2.06 1.51 1.49, 1.53 1.02 0.76, 1.37
Telithromycin (Outcome: Acute Hepatotoxicity)
April 1, 2004 September 30, 2004 MNC MNC MNC
April 1, 2004 December 31, 2004 MNC 5.88 5.09, 6.80 MNC
April 1, 2004 March 31, 2005 12.00 1.56, 92.29 2.76 2.54, 3.00 4.35 0.56, 33.48
April 1, 2004 June 30, 2005 3.25 1.06, 9.97 1.75 1.65, 1.87 1.85 0.60, 5.69
April 1, 2004 September 30, 2005 1.86 0.74, 4.65 1.44 1.36, 1.53 1.29 0.51, 3.23
April 1, 2004 December 31, 2005 2.25 0.98, 5.17 1.47 1.40, 1.55 1.53 0.66, 3.52
April 1, 2004 March 31, 2006 1.90 0.88, 4.09 1.35 1.29, 1.41 1.41 0.65, 3.04
April 1, 2004 June 30, 2006 1.82 0.87, 3.79 1.21 1.16, 1.27 1.50 0.72, 3.13
April 1, 2004 September 30, 2006 1.82 0.87, 3.79 1.16 1.11, 1.21 1.56 0.75, 3.27
April 1, 2004 December 31, 2006 1.82 0.87, 3.79 1.18 1.13, 1.23 1.54 0.74, 3.22

Abbreviations: CI, confidence interval; EOR, exposure odds ratio; MNC, model did not converge.

a Matched on age, sex, and index date of matched case.